Medical technology companies urged not to overlook the Chinese market opportunity
This article was originally published in Clinica
Western companies should take a hard look at how they could best exploit a relatively new market that is growing at 15% per year, says Morgan Stanley analyst Glenn Reicin
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.